Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients

Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients

© 2017 Elsevier B.V. and International Society of Chemotherapy There is evidence that Thai patients receiving standard doses of ritonavir (RTV)-boosted atazanavir (ATV/r) have high exposure to atazanavir (ATV) leading to a higher risk of toxicity. A lower dose of ATV/r may provide adequate exposure...

Saved in:

書目詳細資料
Main Authors:	Baralee Punyawudho, Narukjaporn Thammajaruk, Kiat Ruxrungtham, Anchalee Avihingsanon
格式:	雜誌
出版:	2018
主題:	Medicine
在線閱讀:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85011066657&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/57747
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients
由: Baralee Punyawudho, et al.
出版: (2018)

Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients
由: Punyawudho B., et al.
出版: (2017)

Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients
由: Noppaket Singkham, et al.
出版: (2022)

Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients
由: Singkham N.
出版: (2023)

Pharmacokinetic parameters of atazanavir in ritonavir-boosted combination therapy in Thai healthy volunteers : comparison between reduced doses of ritonavir or atazanavir
由: Chankit Puttilerpong
出版: (2011)

Pharmacokinetics of Atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate
由: Torsak Bunupuradah, et al.
出版: (2018)

Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients
由: Baralee Punyawudho, et al.
出版: (2018)

Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients
由: Baralee Punyawudho, et al.
出版: (2018)

Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
由: Kanokrat Rungtivasuwan, et al.
出版: (2018)

Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
由: Kanokrat Rungtivasuwan, et al.
出版: (2018)

Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
由: Kanokrat Rungtivasuwan, et al.
出版: (2018)

Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial
由: Torsak Bunupuradah, et al.
出版: (2018)

Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients
由: Noppaket Singkham, et al.
出版: (2019)

Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients
由: Noppaket Singkham, et al.
出版: (2020)

Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir
由: Weerawat Manosuthi, et al.
出版: (2018)

Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients
由: Kanokrat Rungtivasuwan, et al.
出版: (2018)

Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients
由: Kanokrat Rungtivasuwan, et al.
出版: (2018)

Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic–Pharmacogenetic Model of HIV-infected Patients in Thailand
由: Piyawat Chaivichacharn, et al.
出版: (2020)

Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study
由: Srichatrapimuk S.
出版: (2023)

Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study
由: Srichatrapimuk S.
出版: (2023)

Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy
由: Regis Kreitchmann, et al.
出版: (2018)

Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy
由: Regis Kreitchmann, et al.
出版: (2018)

Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy with Hypercholesterolemia: A Randomized Controlled Trial
由: Phanthaboon Wangpatharawanit, et al.
出版: (2018)

Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults
由: Tim R. Cressey, et al.
出版: (2018)

Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults
由: Cressey T., et al.
出版: (2017)

Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients
由: Baralee Punyawudho, et al.
出版: (2018)

Effects of pitavastatin on lipid profiles in HIV-infected patients with dyslipidemia and receiving atazanavir/ritonavir: A randomized, double-blind, crossover study
由: Asita Wongprikorn, et al.
出版: (2018)

Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling
由: Stein Schalkwijk, et al.
出版: (2019)

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults
由: Siwalee Rattanapunya, et al.
出版: (2018)

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults
由: Siwalee Rattanapunya, et al.
出版: (2018)

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
由: Weerawat Manosuthi, et al.
出版: (2018)

External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients
由: Dinko Rekić, et al.
出版: (2018)

Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged ≥7 years
由: Kulkanya Chokephaibulkit, et al.
出版: (2018)

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
由: Pauline Byakika-Kibwika, et al.
出版: (2018)

Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy
由: Ahizechukwu C. Eke, et al.
出版: (2020)

Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand
由: Heather Bailey, et al.
出版: (2018)

Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand
由: Bailey H., et al.
出版: (2017)

Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers
由: Polina German, et al.
出版: (2018)

Pharmacokinetics and efficacy of darunavir/ritonavir once daily in virologically suppressed, treatment-experienced HIV-infected children
由: K. Chokephaibulkit, et al.
出版: (2018)

Pharmacokinetics and efficacy of darunavir/ritonavir once daily in virologically suppressed, treatment-experienced HIV-infected children
由: Chokephaibulkit K., et al.
出版: (2014)